Document:

Exhibit 4.2.1

 Exhibit 4.2.1 
 FIRST AMENDMENT TO AMENDED AND RESTATED FINANCING AND SECURITY AGREEMENT 
 THIS FIRST AMENDMENT TO AMENDED AND RESTATED FINANCING AND SECURITY AGREEMENT (this “Agreement”) made
as of this 9th day of October, 2009, by and between
CATALYST HEALTH SOLUTIONS, INC., a corporation organized under the laws of the State of Delaware (formerly known as Healthextras, Inc.) (the “Borrower”) and WACHOVIA BANK, NATIONAL ASSOCIATION, a national banking association, its
successors and assigns (the “Lender”). 
 RECITALS 
 A. The Lender has provided the Borrower with (i) a revolving credit facility in the maximum principal amount of Fifty Million Dollars
($50,000,000) as evidenced by that certain Sixth Amended and Restated Revolving Credit Promissory Note from the Borrower in favor of the Lender dated September 15, 2006 and (ii) as part of that revolving credit facility, a standby letter
of credit facility in the maximum principal amount of Twenty Million Dollars ($20,000,000), each of which are governed by that certain Amended and Restated Financing and Security Agreement by and between the Borrower and the Lender dated
September 15, 2006 (as amended, modified, restated, substituted, extended and renewed at any time and from time to time, the “Financing Agreement”). All defined terms used in this Agreement and not defined herein shall have the
meaning given to such terms in the Financing Agreement. 
 B. The Borrower has requested that the Lender (i) increase the
maximum principal amount of the revolving credit facility to One Hundred Million Dollars ($100,000,000), (ii) extend the Revolving Credit Expiration Date, and (iii) make certain other revisions to the Financing Agreement as more fully set
forth herein, and the Lender has agreed on the condition, among others, that this Agreement be executed and delivered by the Borrower to the Lender. 
 NOW, THEREFORE, in consideration of the premises, the mutual agreements herein contained, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
Borrower and the Lender hereby agree as follows: 
 1. Recitals. The parties hereto acknowledge and agree that the above
Recitals are true and correct in all respect and that the same are incorporated herein and made a part hereof by reference. 
 2. Amendments to Financing Agreement. The Financing Agreement is hereby amended as follows: 
 (a)
Section 1.1 (Certain Defined Terms). 
 (i) The following term and its definition are hereby added
to Section 1.1 of the Financing Agreement in alphabetical order: 

 “Inactive Subsidiary” means U.S. Scripts, Inc., a corporation
formed under the laws of the State of Delaware, HealthExtras Benefits Administrator, Inc., a corporation formed under the laws of the State of Delaware, APS Benefits Corporation, a corporation formed under the laws of the State of Delaware, Catalyst
Rx, Inc., a corporation formed under the laws of the State of Delaware, and Catalyst Rx Holdings Corporation, a corporation formed under the laws of the State of Delaware, as the case may be and each of their respective successors and assigns, and
“Inactive Subsidiaries” means each Inactive Subsidiary and each of their respective successors and assigns. 
 (ii) The following terms and their respective definitions in Section 1.1 of the Financing Agreement are hereby amended and restated in their entirety as follows: 
 “Applicable Margin” means the Applicable Margin set forth below; provided, however, that if the Borrower fails to
deliver its quarterly financial statement on the date specified in Section 6.1.1(c), the Applicable Margin shall be 2.75% until such time as the quarterly financial statement is delivered to the Lender: 
  

			
	Funded Debt to
EBITDA	 	Applicable Margin
	 <
1.25
	 	2.00%
	 3 1.25
	 	2.75%

 The Applicable Margin shall be determined and reset on each Interest
Rate Adjustment Date, based on the quarterly financial statement delivered to the Lender for the previous fiscal quarter pursuant to Section 6.1.1(c). 
 “Funded Debt” means at any date, the aggregate of all interest-bearing Indebtedness for Borrowed Money of the
Borrower and its Subsidiaries, whether secured or unsecured including, without limitation, all Subordinated Indebtedness. 
 “Guarantor” means CATALYST CONSULTANTS, a corporation organized under the laws of the State of Nevada, CATALYST RX, a corporation organized under the laws of the State of Nevada, CATALYST RX
GOVERNMENT SERVICES, INC., a corporation organized under the laws of the State of Nevada, MANAGED HEALTHCARE SYSTEMS, INC., a corporation organized under the laws of the State of Florida, CONCEPT PHARMACEUTICALS, LLC, a limited liability company
organized under the laws of the State of Alabama, HOSPISCRIPT SERVICES, LLC, a limited liability company organized under the laws of the State of Delaware, SENIORSCRIPT, LLC, a limited liability company organized under the laws of the State of
Alabama, CATALYST PRX, LLC, a limited liability company organized under the laws of the State of Nevada, CATALYST PRX GOVERNMENT SERVICES, LLC, a limited liability company organized under the laws of the State of Nevada, COALITION FOR ADVANCED
PHARMACY SERVICES, LLC, a limited liability company organized under the laws of the State of

  

 2 

 
Delaware, R/XX PHARMACY SOLUTIONS, INC., a corporation organized under the laws of the State of Arizona, CATALYST RX REBATE MANAGEMENT, INC., a corporation organized under the laws of the State of Nevada, CATALYST RX IPA, INC., a corporation organized
under the laws of the State of New York, IMMEDIATE PHARMACEUTICAL SERVICES, INC., a corporation organized under the laws of the State of Ohio, and TOTAL SCRIPT, L.L.C., a limited liability company organized under the laws of the State of Nevada, and
any future guarantor of the Obligations, as the case may be and each of their respective successors and assigns, and “Guarantors” means each Guarantor and each of their respective successors and assigns. 
 “Guaranty” means that certain Second Amended and Restated Guaranty of Payment for the benefit of the Lender dated
October 9, 2009 to the Lender from the Guarantors, and any future guarantees executed by any Guarantor for the benefit of the Lender, each as may from time to time be amended, restated, supplemented or otherwise modified. 
 “Revolving Credit Expiration Date” means October 9, 2012, unless extended by the Lender in the exercise of
its sole and absolute discretion. 
 (b) Section 2.1.1 (Revolving Credit Facility). Section 2.1.1 of the
Financing Agreement is hereby amended and restated in its entirety as follows: 
 2.1.1. Revolving Credit
Facility. 
 Subject to and upon the provisions of this Agreement, the Lender establishes a revolving credit
facility in favor of the Borrower. During the Revolving Credit Commitment Period, the Borrower may request advances under the Revolving Credit Facility in accordance with the provisions of this Agreement. The aggregate of all advances under the
Revolving Credit Facility is sometimes referred to in this Agreement as the “Revolving Loan”. The principal amount of One Hundred Million Dollars ($100,000,000), as the same may be reduced in accordance with Section 2.1.5 is the
“Revolving Credit Committed Amount”. Unless sooner paid, the unpaid Revolving Loan, together with interest accrued and unpaid thereon, and all other Obligations shall be due and payable in full on the Revolving Credit Expiration Date.

 (c) Section 2.1.7 (Revolving Credit Unused Line Fee). Section 2.1.7 of the Financing Agreement is hereby
amended and restated in its entirety as follows: 
 2.1.7 Revolving Credit Unused Line Fee. 

The Borrower shall pay to the Lender a revolving credit facility fee (collectively, the “Revolving Credit Unused Line
Fees” and individually, a “Revolving Credit Unused Line Fee”) in an amount equal to three hundred seventy five hundredths

  

 3 

 
percent (0.375%) of the average daily unused and undisbursed portion of the Revolving Credit Committed Amount in effect from time to time accruing during each calendar quarter tested as of the
last day of any calendar quarter. The accrued and unpaid portion of the Revolving Credit Unused Line Fee shall be paid by the Borrower to the Lender on the first day of each calendar quarter, commencing on November 1, 2009, and on the Revolving
Credit Termination Date. 
 (d) Section 2.2.2 (Letter of Credit Fees). The first sentence of Section 2.2.2 of
the Financing Agreement is hereby amended and restated in its entirety as follows: 
 Prior to or simultaneously
with the opening of each Letter of Credit, the Borrower shall pay to the Lender, a per annum letter of credit fee (each a “Letter of Credit Fee” and collectively the “Letter of Credit Fees”) in an amount equal to the Applicable
Margin multiplied by the face amount of the Letter of Credit. 
 (e) Section 6.1.3 (Recordkeeping, Rights of Inspection,
Field Examination, Etc.). Sections 6.1.3(b) and 6.1.3(c) of the Financing Agreement are hereby amended and restated in their entirety as follows: 
 (b) The Borrower shall, and shall cause each of its Subsidiaries to, permit authorized representatives of the Lender to visit and inspect the properties of the Borrower and its Subsidiaries, to review,
audit, check and inspect the Collateral at any time with or without notice, to review, audit, check and inspect the Borrower’s other books of record at any time with or without notice and to make abstracts and photocopies thereof, and to
discuss the affairs, finances and accounts of the Borrower and/or any Subsidiaries, with the officers, directors, employees and other representatives of the Borrower and/or any Subsidiaries and their respective accountants, all at such times during
normal business hours and other reasonable times and as often as the Lender may reasonably request; provided, however, that prior to the occurrence of a Default or an Event of Default, (i) the Lender shall give the Borrower reasonable prior
notice of any such audits or inspections and (ii) the Borrower shall not be obligated to pay for more than one (1) audit in any calendar year. 
 (c) The Borrower hereby irrevocably authorizes and, upon the Lender’s request, shall direct all accountants and auditors employed by the Borrower and/or any Subsidiaries at any time prior to the
repayment in full of the Obligations to exhibit and deliver to the Lender copies of any and all of the financial statements, trial balances, management letters, or other accounting records of any nature of the Borrower and/or any Subsidiaries in the
accountant’s or auditor’s possession, and to disclose to the Lender any information they may have concerning the financial status and business operations of the Borrower and its Subsidiaries. Further, the Borrower hereby authorizes all
Governmental Authorities to furnish to the Lender copies of reports or examinations relating to the Borrower and/or any Subsidiaries, whether made by the Borrower or otherwise. 
  

 4 

 (f) Section 6.1.7 (Line of Business). Section 6.1.7 of the Financing
Agreement is hereby amended and restated in its entirety as follows: 
 6.1.7 Line of Business.

 The Borrower will continue to engage substantially only in the business of pharmacy benefit management and
other related healthcare fields. 
 (g) Section 6.1.8 (Insurance). The last sentence of Section 6.1.8 of the
Financing Agreement is hereby amended and restated in its entirety as follows: 
 If the Lender determines that
the Borrower should obtain additional insurance as a result of any change in (a) any Law, (b) what is customary for businesses in the same geographic areas by business entities engaged in the same or similar business, or (c) any
policy of the Lender or other financial institutions, the Borrower will obtain such additional insurance within thirty (30) days after notice in writing from the Lender. 
 (h) Section 6.1.13(a) (Funded Debt to EBITDA). Section 6.1.13(a) of the Financing Agreement is hereby amended and restated
in its entirety as follows: 
 (a) Funded Debt to EBITDA. The Borrower shall maintain a ratio of Funded Debt to
EBITDA, tested as of the last day of each of the Borrower’s fiscal quarters for the four (4) quarter period ending on that date, of not greater than 2.00 to 1.00. 
 (i) Section 6.1.18 (Business Names; Locations). Section 6.1.18 of the Financing Agreement is hereby amended and restated in
its entirety as follows: 
 6.1.18 Business Names; Locations. 
 The Borrower will notify and cause each of its Subsidiaries to notify the Lender not less than thirty (30) days prior to (a) any
change in the name under which the Borrower or the applicable Subsidiary conducts its business, (b) any change of the location of the chief executive office of the Borrower or the applicable Subsidiary, (c) the opening of any new place of
business or the closing of any existing place of business if such new or closed place of business either has twenty-five (25) or more employees or the aggregate value of Collateral, maintained in such place of business exceeds Three Million
Dollars ($3,000,000), and (d) any change in the location of the places where the Collateral, or any part thereof, where the change in the aggregate value of Collateral at such location exceeds Three Million Dollars ($3,000,000) or any change in
the location of the places where the books and records, or any part thereof, are kept. 
 (j) Section 6.2.1 (Merger,
Acquisition or Consolidation). The following sentence is hereby added after the last sentence of Section 6.2.1 of the Financing Agreement: 
 If the outstanding principal balance of the Revolving Loan is greater than or equal to Seventy-Five Million Dollars ($75,000,000) at the time of the closing of any proposed acquisition, merger or
consolidation (an “Acquisition Transaction”), then prior to closing such Acquisition Transaction, the Borrower shall provide evidence to Lender that the Borrower’s Funded Debt to

  

 5 

 
EBITDA, tested as of the day of the closing of each such Acquisition Transaction and after giving effect to each such Acquisition Transaction on a pro-forma basis, will not be greater than 1.75
to 1.00. 
 (k) Section 6.2.2 (Subsidiaries). Section 6.2.2 of the Financing Agreement is hereby amended and
restated in its entirety as follows: 
 6.2.2 Subsidiaries. 
 The Borrower will not (a) permit any Subsidiaries to exist other than the Subsidiaries identified on EXHIBIT D, (b) create
or acquire any additional Subsidiaries, or (c) permit any Inactive Subsidiary to become active or operational unless such Inactive Subsidiary first executes and delivers to Lender in form and substance satisfactory to Lender (i) a Guaranty
of Payment Agreement, (ii) a Security Agreement, (iii) an opinion of counsel and (iv) such additional documents as Lender may require to perfect a first priority lien on the assets of such Inactive Subsidiary described in the Security
Agreement. 
 (l) Section 6.2.5 (Indebtedness). Section 6.2.5(g) of the Financing Agreement is hereby amended
and restated in its entirety as follows: 
 (g) additional Indebtedness incurred in the ordinary course of
business not to exceed Twenty Million Dollars ($20,000,000) in the aggregate. 
 (m) Section 6.2.6 (Investments, Loans
and Other Transactions). Section 6.2.6(a) of the Financing Agreement is hereby amended and restated in its entirety as follows: 
 (a) any advance to an officer or employee of the Borrower or any Subsidiary for travel or other business expenses in the ordinary course of business, provided that the aggregate amount of all such
advances by the Borrower and its Subsidiaries (taken as a whole) outstanding at any time shall not exceed Five Hundred Thousand Dollars ($500,000); 
 (n) Section 6.2.11 (Other Businesses). Section 6.2.11 of the Financing Agreement is hereby amended and restated in its entirety as follows: 
 6.2.11 Other Businesses. 
 The Borrower and its Subsidiaries will not materially alter the kind or type of Borrower’s business or that of
Borrower’s Subsidiaries or Affiliates, if any, from the kind described in Section 6.1.7. 
 (o) Section 6.2.15
(Transfer of Collateral). The first sentence of Section 6.2.15 of the Financing Agreement is hereby amended and restated in its entirety as follows: 
 The Borrower and the Subsidiaries will not transfer, or permit the transfer, to another location of any material portion of
the Collateral or the books and records related to any of the Collateral unless at the time of such transfer, (a) no Default or

  

 6 

 
Event of Default has occurred and is continuing, and (b) with respect to any transfer of Collateral having an aggregate value exceeding Three Million Dollars ($3,000,000) or the transfer of
any books and records, the Lender has received (i) at least thirty (30) days prior written notice and (ii) a duly executed landlord waiver for the new location acceptable to the Lender and its counsel in their sole but reasonable
discretion. 
 (p) Section 7.1.8 (Judgment). Section 7.1.8 of the Financing Agreement is hereby amended and
restated in its entirety as follows: 
 7.1.8 Judgment. 
 Unless adequately insured in the opinion of the Lender, the entry of a final judgment for the payment of money involving more
than Two Million Dollars ($2,000,000) against the Borrower or any Subsidiary, and the failure by the Borrower or such Subsidiary to discharge the same, or cause it to be discharged, within thirty (30) days from the date of the order, decree or
process under which or pursuant to which such judgment was entered, or to secure a stay of execution pending appeal of such judgment. 
 (q) Section 7.1.10 (Default Under Other Borrowings). Section 7.1.10 of the Financing Agreement is hereby amended and restated in its entirety as follows: 
 7.1.10 Default Under Other Borrowings. 
 Default shall be made with respect to any Indebtedness for Borrowed Money (other than the Loan) in an amount individually or
in the aggregate in excess of Two Million Dollars ($2,000,000) if the default is a failure to pay at maturity or if the effect of such default is to accelerate the maturity of such Indebtedness for Borrowed Money or to permit the holder or obligee
thereof or other party thereto to cause such Indebtedness for Borrowed Money to become due prior to its stated maturity. 
 (r)
Section 7.1.11 (Material Adverse Change). Section 7.1.11 of the Financing Agreement is hereby amended and restated in its entirety as follows: 
 7.1.11 Material Adverse Change. 
 The Lender, in its sole but reasonable discretion, determines in good faith that a Material Adverse Effect is occurring or
has occurred. 
 (s) Section 8.1 (Notices). Lender’s and Borrower’s addresses set forth in
Section 8.1 of the Financing Agreement are hereby amended and restated in their entirety as follows: 
  

 7 

			
	 Borrower:
	    	Catalyst Health Solutions, Inc.
		    	800 King Farm Boulevard
		    	Rockville, Maryland 20850
		    	Attention: Hai Tran, Chief Financial Officer
		    	
	 Lender:
	    	Wachovia Bank, National Association
		    	1753 Pinnacle Drive, VA 1993
		    	McLean, Virginia 22102
		    	Attention: Barbara K. Angel

 (t) Subsidiaries. Exhibit “D” to the Financing Agreement is
hereby amended and restated in its entirety with Exhibit “D” attached hereto. 
 (u) Compliance
Certificate. Exhibit “E” to the Financing Agreement is hereby amended and restated in its entirety with Exhibit “E” attached hereto. 
 3. Restated Guaranty and Restated Security Agreement. The Guarantors shall execute and deliver to the Lender (a) a Second Amended and Restated Guaranty of Payment Agreement in substantially
the form of Exhibit B attached hereto (the “Restated Guaranty”) pursuant to which they shall jointly and severally guaranty the repayment in full of the Obligations, and (b) a Second Amended and Restated Security
Agreement in substantially the form of Exhibit B attached hereto (the “Restated Security Agreement”) pursuant to which they shall grant a first priority security interest in substantially all of their assets to Lender to
secure the repayment and performance of the Obligations. 
 4. Conditions Precedent. This Agreement shall not become
effective until the Lender receives the following, each of which shall be satisfactory in form and substance to the Lender: 
 (a) The Seventh Amended and Restated Revolving Credit Note by Borrower in favor of the Lender in the maximum principal amount of One Hundred Million Dollars ($100,000,000) dated of even date herewith substantially in the form of Exhibit
C attached hereto; 
 (b) The Restated Guaranty, together with copies of the organizational documents for each Guarantor;

 (c) The Restated Security Agreement; 
 (d) A certificate of good standing certified by the Secretary of State, or other appropriate Governmental Authority, of the state of formation for each Guarantor; 
 (e) A certificate of qualification to do business certified by the Secretary of State or other Governmental Authority of each state in which
each Guarantor conducts business; 
 (f) A certificate dated as of the date hereof by the Secretary or an Assistant Secretary or
manager of each Guarantor, as applicable, covering: 
  

 8 

 (i) true and complete copies of the Guarantor’s organizational and
governing documents and all amendments thereto; 
 (ii) true and complete copies of the resolutions of the Board
of Directors or manager of the Guarantor authorizing the execution, delivery and performance of the Financing Documents to which the Guarantor is a party and the granting of the Liens contemplated by any of the Financing Documents to which the
Guarantor is a party; 
 (iii) the incumbency, authority and signatures of the officers or other authorized
Persons of the Guarantor authorized to sign the Restated Guaranty, the Restated Security Agreement and all other Financing Documents to which the Guarantor is a party; 
 (iv) the identity of the Guarantor’s current members, directors, common stock holders and other equity holders, as well
as their respective percentage ownership interests. 
 (g) (i) All Financing Documents required to be filed, registered or
recorded in order to create, in favor of the Lender, a perfected Lien in the Collateral of each Guarantor (subject only to the Permitted Liens) in form and in sufficient number for filing, registration, and recording in each office in each
jurisdiction in which such filings, registrations and recordations are required, (ii) such evidence as the Lender deems satisfactory that all necessary filing fees and all recording and other similar fees, and all Taxes and other expenses
related to such filings, registrations and recordings will be or have been paid in full, and (iii) certified copies, dated as of a recent date, of financing statement searches, as the Lender shall request, accompanied by written evidence
(including any UCC termination statements) that the Liens indicated in any such financing statements constitute Permitted Liens; 
 (h) The Extension Fee; 
 (i) Proof that the Borrower has paid all fees, costs and out-of-pocket expenses to the Lender
in connection with this Agreement, including, but not limited to, all the Lender’s reasonable attorneys fees; and 
 (j)
Such other information, instruments, opinions, documents, certificates and reports as the Lender may deem necessary. 
 5.
Extension Fee. In consideration of Lender’s agreement to enter into this Agreement, the Borrower shall pay to the Lender a non refundable extension fee (the “Extension Fee”) on the date hereof in the amount of Three Hundred
Seventy-Five Thousand Dollars ($375,000). 
 6. Fees and Expenses. In consideration of the Lender’s agreement to
amend the Financing Agreement, the Borrower shall pay to Lender all of Lender’s reasonable legal fees and expenses in connection with the negotiation and preparation of this Agreement. 
  

 9 

 7. Counterparts. This Agreement may be executed in any number of duplicate originals
or counterparts, each of which duplicate original or counterpart shall be deemed to be an original and all taken together shall constitute one and the same instrument. 
 8. Financing Documents; Governing Law; Etc. This Agreement is one of the Financing Documents defined in the Financing Agreement and shall be governed and construed in accordance with the laws of
the State of Maryland. The headings and captions in this Agreement are for the convenience of the parties only and are not a part of this Agreement. 
 9. Acknowledgments. The Borrower hereby confirms to the Lender the enforceability and validity of each of the Financing Documents. In addition, the Borrower hereby agrees to the execution and
delivery of this Agreement and the terms and provisions, covenants or agreements contained in this Agreement shall not in any manner release, impair, lessen, modify, waive or otherwise limit the liability and obligations of the Borrower under the
terms of any of the Financing Documents, except as otherwise specifically set forth in this Agreement. The Borrower issues, ratifies and confirms the representations, warranties and covenants contained in the Financing Documents as updated through
June 30, 2009. 
 10. Modifications. This Agreement may not be supplemented, changed, waived, discharged,
terminated, modified or amended, except by written instrument executed by the parties. 
 [Signatures Appear on the Following
Page] 
  

 10 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed and delivered
under seal by the duly authorized representatives as of the date and year first written above. 
  

					
	 WITNESS:
	  	CATALYST HEALTH SOLUTIONS, INC.
		  	
		  	
	 /s/ Jennifer Hadley
	  	By:	  	/s/ David T. Blair
                                        
(SEAL)
	Jennifer Hadley	  		  	Name: David T. Blair
		  		  	Title: Chief Executive Officer

  
  

					
	 WITNESS:
	  	WACHOVIA BANK, NATIONAL ASSOCIATION
		  	
		  	
	 /s/ Jennifer Hadley
	  	By:	  	/s/ Barbara
Angel                                        
(SEAL)
	Jennifer Hadley	  		  	Barbara Angel, Senior Vice President

 Signature Page 
 First Amendment to Amended and Restated Financing and Security Agreement 

 EXHIBIT A 
 RESTATED GUARANTY 
 [Intentionally Omitted] 

 EXHIBIT B 
 RESTATED SECURITY AGREEMENT 
 [Intentionally Omitted] 

 EXHIBIT C 
 RESTATED NOTE 

 SEVENTH AMENDED AND RESTATED REVOLVING CREDIT NOTE 
  

			
	$100,000,000	  	McLean, Virginia
		  	October 9, 2009

 FOR VALUE RECEIVED, CATALYST HEALTH SOLUTIONS, INC., a corporation organized under
the laws of the State of Delaware (formerly known as Healthextras, Inc.) (the “Borrower”), promises to pay to the order of WACHOVIA BANK, NATIONAL ASSOCIATION, a national banking association, its successors and assigns (the
“Lender”), the principal sum of ONE HUNDRED MILLION DOLLARS ($100,000,000) (the “Principal Sum”), or so much thereof as has been or may be advanced or readvanced (each an “Advance” and collectively,
“Advances”) to or for the account of the Borrower pursuant to the terms and conditions of the Financing Agreement (as hereinafter defined), together with interest thereon at the rate hereinafter provided, in accordance with the following:

 1. Interest. 
 Interest shall accrue on the unpaid principal balance of this Note from the date hereof at the LIBOR Rate, plus the Applicable Margin (as defined in the Financing Agreement) (the “Interest
Rate”). Interest for each Interest Period shall accrue each day during such Interest Period, commencing on and including the first day to but excluding the last day. “Interest Period” means, in respect of each Advance, each period
commencing on the last day of the immediately preceding Interest Period and ending on the same day of the month that interest in respect of such Advance is due 1 month thereafter; provided (i) the first Interest Period shall commence on the
date of such Advance and end on the first day thereafter that interest in respect of such Advance is due, (ii) any Interest Period that ends in a month for which there is no day which numerically corresponds to the last day of the immediately
preceding Interest Period shall end on the last day of the month and (iii) any Interest Period that would otherwise extend past the maturity date of this Note shall end on the Revolving Credit Expiration Date. “LIBOR Rate” means, with
respect to each Interest Period, the rate for U.S. dollar deposits with a maturity equal to the one month, as reported on Telerate Successor page 3750 as of 11:00 a.m., London time, on the second London business day before such Interest Period
begins (or if not so reported, then as determined by the Lender from another recognized source or interbank quotation). Borrower shall indemnify Lender against Lender’s loss or expense as a consequence of (a) Borrower’s failure to
make any payment when due under this Note, (b) any payment or prepayment of any loan on a day other than the last day of the Interest Period, or (c) any failure to make a borrowing after giving notice thereof (“Indemnified Loss or
Expense”). The amount of such Indemnified Loss or Expense shall be determined by Lender based upon the assumption that Lender funded 100% of that portion of the loan in the London interbank market. All interest payable under the terms of this
Note shall be calculated on the basis of a 360-day year and the actual number of days elapsed. 

 2. Payments and Maturity. 
 The unpaid Principal Sum, together with interest thereon at the rate provided above, shall be payable as follows: 
 Interest only on the unpaid Principal Sum shall be due and payable monthly, commencing November 1, 2009, and on the first day of each
month thereafter to maturity; and 
 Unless sooner paid, the unpaid Principal Sum, together with interest accrued and unpaid
thereon, shall be due and payable in full on the Revolving Credit Expiration Date. 
 The fact that the balance hereunder may be
reduced to zero from time to time pursuant to the Financing Agreement will not affect the continuing validity of this Note or the Financing Agreement, and the balance may be increased to the Principal Sum after any such reduction to zero.

 Borrower authorizes Lender to debit its demand deposit account
#                 with Lender for any payments due under this Note. Borrower further certifies that Borrower holds legitimate ownership of this account and preauthorizes
this periodic debit as part of its right under said ownership. 
 3. Default Interest. 
 Upon the occurrence of an Event of Default (as hereinafter defined), the unpaid Principal Sum shall, at the option of Lender bear interest
thereafter at the Post-Default Rate until such Event of Default is cured. 
 4. Application and Place of Payments.

 All payments, made on account of this Note shall be applied first to the payment of accrued and unpaid interest then due
hereunder, and the remainder, if any, shall be applied to the unpaid Principal Sum. All payments on account of this Note shall be paid in lawful money of the United States of America in immediately available funds during regular business hours of
the Lender at its principal office in McLean, Virginia or at such other times and places as the Lender may at any time and from time to time designate upon five (5) Business Days’ notice in writing to the Borrower. 
 5. Prepayment. 
 The Borrower may prepay the Principal Sum in whole or in part at any time without premium or penalty. 
 6.
Financing Agreement and Other Financing Documents. 
 This Note is the “Seventh Amended and Restated Revolving
Credit Note” described in that certain First Amendment to Amended and Restated Financing and Security Agreement dated of even date herewith by and between the Borrower and the Lender, which amends that certain Amended and Restated Financing and
Security Agreement dated September 15, 2006 by and between the

  

 2 

 
Borrower and the Lender (the Amended and Restated Financing and Security Agreement as amended, modified, restated, substituted, extended and renewed at any time and from time to time, is
hereinafter called, the “Financing Agreement”). The indebtedness evidenced by this Note increases, amends and restated in its entirety that certain Sixth Amended and Restated Revolving Credit Note dated September 15, 2006 (the
“Prior Note”) in the maximum principal amount of Fifty Million Dollars ($50,000,000) from the Borrower in favor of the Lender. It is expressly agreed that the indebtedness evidenced by the Prior Note has not been extinguished or discharged
hereby. The Borrower and the Lender agree that the execution of this Note is not intended to and shall not cause or result in a novation with respect to the Prior Note. The indebtedness evidenced by this Note is included within the meaning of the
term “Obligations” as defined in the Financing Agreement. The term “Financing Documents” as used in this Note shall mean collectively this Note, the Financing Agreement and any other instrument, agreement, or document previously,
simultaneously, or hereafter executed and delivered by the Borrower and/or any other person, singularly or jointly with any other person, evidencing, securing, guaranteeing, or in connection with the Principal Sum, this Note and/or the Financing
Agreement, but does not include swap agreements (as defined in 11 U.S.C. §101). 
 7. Security. 
 This Note is secured as provided in the Financing Agreement. 
 8. Events of Default. 
 The occurrence of any one or more of the following
events shall constitute an event of default (individually, an “Event of Default” and collectively, the “Events of Default”) under the terms of this Note: 
 The failure of the Borrower to pay to the Lender within five (5) Business Days of when due any and all amounts payable by the Borrower
to the Lender under the terms of this Note; or 
 The occurrence of an Event of Default (as defined therein) under the terms and
conditions of any of the other Financing Documents. 
 9. Remedies. 
 Upon the occurrence of an Event of Default, at the option of the Lender, all amounts payable by the Borrower to the Lender under the terms
of this Note shall immediately become due and payable by the Borrower to the Lender without notice to the Borrower or any other person, and the Lender shall have all of the rights, powers, and remedies available under the terms of this Note, any of
the other Financing Documents and all applicable laws. The Borrower and all endorsers, guarantors, and other parties who may now or in the future be primarily or secondarily liable for the payment of the indebtedness evidenced by this Note hereby
severally waive presentment, protest and demand, notice of protest, notice of demand and of dishonor and non-payment of this Note and expressly agree that this Note or any payment hereunder may be extended from time to time without in any way
affecting the liability of the Borrower, guarantors and endorsers. 
  

 3 

 10. Confessed Judgment. 
 Upon the occurrence of an Event of Default, the Borrower hereby authorizes any attorney designated by the Lender or any clerk of any court
of record to appear for the Borrower in any court of record and confess judgment without prior hearing against the Borrower in favor of the Lender for and in the amount of the unpaid Principal Sum, all interest accrued and unpaid thereon, all other
amounts payable by the Borrower to the Lender under the terms of this Note or any of the other Financing Documents, costs of suit, and attorneys’ fees of five percent (5%) of the unpaid Principal Sum and interest then due hereunder. By its
acceptance of this Note, the Lender agrees that in the event the Lender exercises at any time its right to confess judgment under this Note, the Lender shall use its best efforts to obtain legal counsel who will charge the Lender for its services on
an hourly basis, at its customary hourly rates and only for the time and reasonable expenses incurred. In no event shall the Lender enforce the legal fees portion of a confessed judgment award for an amount in excess of the fees and expenses
actually charged to the Lender for services rendered by its counsel in connection with such confession of judgment and/or the collection of sums owed to the Lender. In the event the Lender receives, through execution upon a confessed judgment,
payments on account of attorneys’ fees in excess of such actual attorneys’ fees and expenses incurred by the Lender, then, after full repayment and satisfaction of all of the obligations under and in connection with this Note, the
Financing Agreement and all of the other Financing Documents, the Lender shall refund such excess amount to the Borrower. The Borrower hereby releases, to the extent permitted by applicable law, all errors and all rights of exemption, appeal, stay
of execution, inquisition, and other rights to which the Borrower may otherwise be entitled under the laws of the United States of America or of any state or possession of the United States of America now in force or which may hereafter be enacted.
The authority and power to appear for and enter judgment against the Borrower shall not be exhausted by one or more exercises thereof or by any imperfect exercise thereof and shall not be extinguished by any judgment entered pursuant thereto. Such
authority may be exercised on one or more occasions or from time to time in the same or different jurisdictions as often as the Lender shall deem necessary or desirable, for all of which this Note shall be a sufficient warrant. 
 11. Expenses. 
 The Borrower promises to pay to the Lender on demand by the Lender all costs and expenses incurred by the Lender in connection with the collection and enforcement of this Note, including, without limitation, reasonable attorneys’ fees
and expenses and all court costs. 
 12. Notices. 
 Any notice, request, or demand to or upon the Borrower or the Lender shall be deemed to have been properly given or made when delivered in
accordance with Section 8.1 of the Financing Agreement. 
  

 4 

 13. Miscellaneous. 
 Each right, power, and remedy of the Lender as provided for in this Note or any of the other Financing Documents, or now or hereafter
existing under any applicable law or otherwise shall be cumulative and concurrent and shall be in addition to every other right, power, or remedy provided for in this Note or any of the other Financing Documents or now or hereafter existing under
any applicable law, and the exercise or beginning of the exercise by the Lender of any one or more of such rights, powers, or remedies shall not preclude the simultaneous or later exercise by the Lender of any or all such other rights, powers, or
remedies. No failure or delay by the Lender to insist upon the strict performance of any term, condition, covenant, or agreement of this Note or any of the other Financing Documents, or to exercise any right, power, or remedy consequent upon a
breach thereof, shall constitute a waiver of any such term, condition, covenant, or agreement or of any such breach, or preclude the Lender from exercising any such right, power, or remedy at a later time or times. By accepting payment after the due
date of any amount payable under the terms of this Note, the Lender shall not be deemed to waive the right either to require prompt payment when due of all other amounts payable under the terms of this Note or to declare an Event of Default for the
failure to effect such prompt payment of any such other amount. No course of dealing or conduct shall be effective to amend, modify, waive, release, or change any provisions of this Note. The Borrower represents and warrants to Lender that none of
Borrower, or any subsidiary or affiliate of Borrower or any guarantor is a Sanctioned Person or has any of its assets in a Sanctioned Country or does business in or with, or derives any of its operating income from investments in or transactions
with, Sanctioned Persons or Sanctioned Countries in violation of economic sanctions administered by OFAC. The proceeds from the Revolving Loan will not be used to fund any operations in, finance any investments or activities in, or make any payments
to, a Sanctioned Person or a Sanctioned Country. “OFAC” means the U.S. Department of the Treasury’s Office of Foreign Assets Control. “Sanctioned Country” means a country subject to a sanctions program identified on the list
maintained by OFAC and available at http://www.treas.gov/offices/enforcement/ofac/sanctions/, or as otherwise published from time to time. “Sanctioned Person” means (i) a person named on the list of Specially Designated Nationals or
Blocked Persons maintained by OFAC available at http://www.treas.gov/offices/enforcement/ofac/sdn/, or as otherwise published from time to time, or (ii) (A) an agency of the government of a Sanctioned Country, (B) an organization
controlled by a Sanctioned Country, or (C) a person resident in a Sanctioned Country to the extent subject to a sanctions program administered by OFAC. 
 14. Partial Invalidity. 
 In the event any provision of this Note (or any
part of any provision) is held by a court of competent jurisdiction to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision (or remaining part of the affected
provision) of this Note; but this Note shall be construed as if such invalid, illegal, or unenforceable provision (or part thereof) had not been contained in this Note, but only to the extent it is invalid, illegal, or unenforceable. 
  

 5 

 15. Captions. 
 The captions herein set forth are for convenience only and shall not be deemed to define, limit, or describe the scope or intent of this
Note. 
 16. Applicable Law. 
 The Borrower acknowledges and agrees that this Note shall be governed by the laws of the State of Maryland, even though for the convenience and at the request of the Borrower, this Note may be executed
elsewhere. 
 17. Business Purpose. 
 The Borrower represents and warrants that it is not a natural person and that the obligations evidenced by this Note were not incurred for personal, family or household purposes. 
 18. Consent to Jurisdiction. 
 The Borrower irrevocably submits to the jurisdiction of any state or federal court sitting in the State of Maryland over any suit, action, or proceeding arising out of or relating to this Note or any of
the other Financing Documents. The Borrower irrevocably waives, to the fullest extent permitted by law, any objection that the Borrower may now or hereafter have to the laying of venue of any such suit, action, or proceeding brought in any such
court and any claim that any such suit, action, or proceeding brought in any such court has been brought in an inconvenient forum. Final judgment in any such suit, action, or proceeding brought in any such court shall be conclusive and binding upon
the Borrower and may be enforced in any court in which the Borrower is subject to jurisdiction by a suit upon such judgment, provided that service of process is effected upon the Borrower as provided in this Note or as otherwise permitted by
applicable law. 
 19. Service of Process. 
 The Borrower hereby consents to process being served in any suit, action, or proceeding instituted in connection with this Note by (a) the mailing of a copy thereof by certified mail, postage
prepaid, return receipt requested, to the Borrower and (b) serving a copy thereof upon The CT Corporation, 1209 Orange Street, Wilmington, Delaware 19801, the agent hereby designated and appointed by the Borrower as the Borrower’s agent
for service of process. The Borrower irrevocably agrees that such service shall be deemed in every respect effective service of process upon the Borrower in any such suit, action or proceeding, and shall, to the fullest extent permitted by law, be
taken and held to be valid personal service upon the Borrower. Nothing in this Section shall affect the right of the Lender to serve process in any manner otherwise permitted by law or limit the right of the Lender otherwise to bring proceedings
against the Borrower in the courts of any jurisdiction or jurisdictions. 
  

 6 

 20. WAIVER OF TRIAL BY JURY. 
 THE BORROWER AND THE LENDER HEREBY WAIVE TRIAL BY JURY IN ANY ACTION OR PROCEEDING TO WHICH THE BORROWER AND THE LENDER MAY BE PARTIES,
ARISING OUT OF OR IN ANY WAY PERTAINING TO (A) THIS NOTE OR (B) THE FINANCING DOCUMENTS. IT IS AGREED AND UNDERSTOOD THAT THIS WAIVER CONSTITUTES A WAIVER OF TRIAL BY JURY OF ALL CLAIMS AGAINST ALL PARTIES TO SUCH ACTIONS OR PROCEEDINGS,
INCLUDING CLAIMS AGAINST PARTIES WHO ARE NOT PARTIES TO THIS NOTE. 
 THIS WAIVER IS KNOWINGLY, WILLINGLY AND VOLUNTARILY
MADE BY THE BORROWER, AND THE BORROWER HEREBY REPRESENTS THAT NO REPRESENTATIONS OF FACT OR OPINION HAVE BEEN MADE BY ANY INDIVIDUAL TO INDUCE THIS WAIVER OF TRIAL BY JURY OR TO IN ANY WAY MODIFY OR NULLIFY ITS EFFECT. THE BORROWER FURTHER
REPRESENTS THAT IT HAS BEEN REPRESENTED IN THE SIGNING OF THIS NOTE AND IN THE MAKING OF THIS WAIVER BY INDEPENDENT LEGAL COUNSEL, SELECTED OF ITS OWN FREE WILL, AND THAT IT HAS HAD THE OPPORTUNITY TO DISCUSS THIS WAIVER WITH COUNSEL.

 21. LIMITATION ON LIABILITY; WAIVER OF PUNITIVE DAMAGES. 
 EACH OF THE PARTIES HERETO, INCLUDING THE LENDER BY ACCEPTANCE HEREOF, AGREES THAT IN ANY JUDICIAL, MEDIATION OR ARBITRATION PROCEEDING OR
ANY CLAIM OR CONTROVERSY BETWEEN OR AMONG THEM THAT MAY ARISE OUT OF OR BE IN ANY WAY CONNECTED WITH THIS NOTE, THE OTHER FINANCING DOCUMENTS OR ANY OTHER AGREEMENT OR DOCUMENT BETWEEN OR AMONG THEM OR THE OBLIGATIONS EVIDENCED HEREBY OR RELATED
HERETO, IN NO EVENT SHALL ANY PARTY HAVE A REMEDY OF, OR BE LIABLE TO THE OTHER FOR, (1) INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OR (2) PUNITIVE OR EXEMPLARY DAMAGES. EACH OF THE PARTIES HEREBY EXPRESSLY WAIVES ANY RIGHT OR CLAIM TO
PUNITIVE OR EXEMPLARY DAMAGES THEY MAY HAVE OR WHICH MAY ARISE IN THE FUTURE IN CONNECTION WITH ANY SUCH PROCEEDING, CLAIM OR CONTROVERSY, WHETHER THE SAME IS RESOLVED BY ARBITRATION, MEDIATION, JUDICIALLY OR OTHERWISE. 
 22. Patriot Act Notice. 
 To help fight the funding of terrorism and money laundering activities, Federal law requires all financial institutions to obtain, verify, and record information that identifies each person who opens an
account. For purposes of this section, account shall be understood to include loan accounts. 
  

 7 

 23. Assignment. 
 Nothing in this Note or any of the other Financing Documents shall prohibit the Lender from pledging or assigning this Note or any of the
other Financing Documents or any interest therein to any Federal Reserve Bank. The Borrower shall not assign its rights and interest hereunder without the prior written consent of the Lender, and any attempt by the Borrower to assign without the
Lender’s prior written consent is null and void. Any assignment shall not release the Borrower from the Obligations. 
 24.
Final Agreement. 
 This Note and the other Financing Documents represent the final agreement between the parties and may
not be contradicted by evidence of prior, contemporaneous or subsequent oral agreements of the parties. There are no unwritten oral agreements between the parties. 
 [Signatures appear on the following page] 
  

 8 

 IN WITNESS WHEREOF, the Borrower has caused this Note to be executed under seal by its duly
authorized officers as of the date first written above. 
  

									
	WITNESS OR ATTEST:	 		 	CATALYST HEALTH SOLUTIONS, INC.	 	
					
	/s/ Jennifer Hadley	 		 	By:	 	/s/ David T. Blair	 	(Seal)
	Jennifer Hadley	 		 		 	Name: David T. Blair	 	
		 		 		 	Title: Chief Executive Officer	 	

 Signature Page 
 Seventh Amended and Restated Revolving Credit Note 

 EXHIBIT D 
 SUBSIDIARIES 
 [Intentionally Omitted] 

 EXHIBIT E 
 COMPLIANCE CERTIFICATE 
 [Intentionally Omitted]Incentive Plan

 Exhibit 10.2 
 ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS INC. 
 INCENTIVE PLAN 
 I. Purposes 
 The purposes of the Allscripts-Misys Healthcare Solutions Inc. Incentive Plan (the “Plan”) are to retain and motivate the officers
and other employees of Allscripts-Misys Healthcare Solutions Inc. and its subsidiaries who have been designated by the Committee to participate in the Plan for a specified Performance Period by providing them with the opportunity to earn incentive
payments based upon the extent to which specified performance goals have been achieved or exceeded for the Performance Period. It is intended that all amounts payable to Participants who are “covered employees” within the meaning of
Section 162(m) of the Code will constitute “qualified performance-based compensation” within the meaning of U.S. Treasury regulations promulgated thereunder, and the Plan and the terms of any Awards hereunder shall be so interpreted
and construed to the maximum extent possible. 
 II. Definitions 
 “Annual Base Salary” shall mean for any Participant an amount equal to the rate of annual base salary
in effect or approved by the Committee or other authorized person at the time or immediately before performance goals are established for a Performance Period, including any base salary that otherwise would be payable to the Participant during the
Performance Period but for his or her election to defer receipt thereof. 
 “Applicable
Period” shall mean, with respect to any Performance Period, a period commencing on or before the first day of the Performance Period and ending not later than the earlier of (a) the 90th day after the commencement of the Performance Period and
(b) the date on which twenty-five percent (25%) of the Performance Period has been completed. Any action required to be taken within an Applicable Period may be taken at a later date if permissible under Section 162(m) of the Code or
U.S. Treasury regulations promulgated thereunder. 
 “Award” shall mean an award to which
a Participant may be entitled under the Plan if the performance goals for a Performance Period are satisfied. An Award may be expressed in U.S. dollars or pursuant to a formula that is consistent with the provisions of the Plan. 
 “Board” shall mean the Board of Directors of the Company. 
 “Code” shall mean the Internal Revenue Code of 1986, as amended. 
 “Committee” shall mean a subcommittee of the Compensation Committee of the Board comprised of the
members of the Compensation Committee of the Board that are “outside directors” within the meaning of Section 162(m) of the Code, or such other committee designated by the Board that satisfies any then applicable requirements of the
principal national stock exchange on which the common stock of the Company is then traded to constitute a compensation committee, and which consists of two or more members of the Board, each of whom is an “outside director” within the
meaning of Section 162(m) of the Code. 
 “Company” shall mean Allscripts-Misys
Healthcare Solutions Inc., a Delaware corporation, and any successor thereto. 
 “Participant” shall mean an officer or other employee of the Company or any of its subsidiaries who is designated by the Committee to participate in the Plan for a Performance Period, in accordance with
Article III. 
  

 1 

 “Performance Period” shall mean any period commencing
on or after June 1, 2009 for which performance goals are established pursuant to Article IV. A Performance Period may be coincident with one or more fiscal years of the Company or a portion of any fiscal year of the Company. 
 “Plan” shall mean the Allscripts-Misys Healthcare Solutions Inc. Incentive Plan as set forth herein,
as it may be amended from time to time. 
 III. Administration 
 3.1. General. The Plan shall be administered by the Committee, which shall have the full power and authority to
interpret, construe and administer the Plan and Awards granted hereunder (including in each case reconciling any inconsistencies, correcting any defaults and addressing any omissions). The Committee’s interpretation, construction and
administration of the Plan and all its determinations hereunder shall be final, conclusive and binding on all persons for all purposes. 
 3.2. Powers and Responsibilities. The Committee shall have the following discretionary powers, rights and responsibilities in addition to those described in
Section 3.1. 
  

	 	(a)	to designate within the Applicable Period the Participants for a Performance Period; 

  

	 	(b)	to establish within the Applicable Period the performance goals and targets and other terms and conditions that are to apply to each Participant’s Award;

  

	 	(c)	to determine in writing prior to the payment with respect to any Award that the performance goals for a Performance Period and other material terms applicable to the
Award have been satisfied; 

  

	 	(d)	subject to Section 409A of the Code, to determine whether, and under what circumstances and subject to what terms, an Award is to be paid on a deferred basis,
including whether such a deferred payment shall be made solely at the Committee’s discretion or whether a Participant may elect deferred payment; and 

  

	 	(e)	to adopt, revise, suspend, waive or repeal, when and as appropriate, in its sole and absolute discretion, such administrative rules, guidelines and procedures for the
Plan as it deems necessary or advisable to implement the terms and conditions of the Plan. 

 3.3.
Delegation of Power. The Committee may delegate some or all of its power and authority hereunder to the Chief Executive Officer or other executive officer of the Company as the Committee deems appropriate; provided,
however, that with respect to any person who is a “covered employee” within the meaning of Section 162(m) of the Code or who, in the Committee’s judgment, is likely to be a covered employee at any time during the
applicable Performance Period or during any period in which an Award may be paid following a Performance Period, only the Committee shall be permitted to (a) designate such person to participate in the Plan for such Performance Period,
(b) establish performance goals and Awards for such person, and (c) certify the achievement of such performance goals. 
 IV. Performance Goals 
 4.1. Establishing Performance Goals. The Committee shall
establish within the Applicable Period of each Performance Period one or more objective performance goals (the outcome of which, when established, shall be substantially uncertain) for each Participant or for any group of Participants (or both).
Performance goals shall be based exclusively on one or more of the following objective corporate-wide or subsidiary, division, operating unit or individual measures: earnings per share; earnings before interest and taxes (“EBIT”); earnings
before interest, taxes, depreciation and amortization (“EBITDA”); earnings as determined other than in accordance with

  

 2 

 
generally accepted accounting principles (“GAAP”); stock price; financial return ratios, consisting of return on equity, return on assets and return on invested capital; the ratio of
EBIT to capital; the ratio of EBITDA to capital; net income; operating income; revenues; profit margin; cash flow(s); expense reduction; working capital ratios; achievement of balance sheet or income statement objectives; successful implementation
of strategic initiatives; customer satisfaction measures; and successful integration of acquisitions. Each such goal may be expressed on an absolute or relative basis and may include comparisons based on current internal targets, the past
performance of the Company (including the performance of one or more subsidiaries, divisions, or operating units) or the past or current performance of other companies (or a combination of such past and current performance). In the case of
earnings-based measures, in addition to the ratios specifically enumerated above, performance goals may include comparisons relating to capital (including, but not limited to, the cost of capital), stockholders’ equity, shares outstanding,
assets or net assets, or any combination thereof. With respect to Participants who are not “covered employees” within the meaning of Section 162(m) of the Code and who, in the Committee’s judgment, are not likely to be covered
employees at any time during the applicable Performance Period or during any period in which an Award may be paid following a Performance Period, the performance goals established for the Performance Period may consist of any objective or subjective
corporate-wide or subsidiary, division, operating unit or individual measures, whether or not listed herein. Performance goals shall be subject to such other special rules and conditions as the Committee may establish at any time within the
Applicable Period; provided, however, that to the extent such goals relate to Awards to “covered employees” within the meaning of Section 162(m) of the Code, such special rules and conditions shall not be inconsistent
with the provisions of Treasury regulation Section 1.162-27(e) or any successor regulation describing “qualified performance-based compensation.” 
 4.2. Impact of Extraordinary Items or Changes in Accounting. The measures utilized in establishing performance goals under the Plan shall, to the extent applicable (i.e., if the
relevant performance goal is based on a GAAP measure), be determined in accordance with GAAP and in a manner consistent with the methods used in the Company’s audited consolidated financial statements, without regard to (a) extraordinary
or other nonrecurring or unusual items, as determined by the Company’s independent public accountants in accordance with GAAP, (b) changes in accounting, as determined by the Company’s independent public accountants in accordance with
GAAP, or (c) special charges, such as restructuring or impairment charges, unless, in each case, the Committee decides otherwise within the Applicable Period or as otherwise required under Section 162(m) of the Code. 
 V. Terms of Awards 
 5.1. Performance Goals and Targets. At the time performance goals are established for a Performance Period, the Committee also shall establish an Award opportunity for each Participant or group of Participants,
which shall be based on the achievement of one or more specified targets of performance goals. The targets shall be expressed in terms of an objective formula or standard which may be based upon the Participant’s Annual Base Salary or a
multiple thereof. In all cases the Committee shall have the sole and absolute discretion to reduce the amount of any payment with respect to any Award that would otherwise be made to any Participant or to decide that no payment shall be made. With
respect to each Award, the Committee may establish terms regarding the circumstances in which a Participant will be entitled to payment notwithstanding the failure to achieve the applicable performance goals or targets (e.g., where the
Participant’s employment terminates due to death or disability or where a change in control of the Company occurs); provided, however, that with respect to any Participant who is a “covered employee” within the meaning
of Section 162(m) of the Code, the Committee shall not establish any such terms that would cause an Award payable upon the achievement of the performance goals not to satisfy the conditions of Treasury regulation Section 1.162-27(e) or any
successor regulation describing the “qualified performance-based compensation.” 
 5.2.
Payments. At the time the Committee determines an Award opportunity for a Participant, the Committee shall also establish the payment terms applicable to such Award. Such terms shall include when such payments will be made;
provided, however, that the timing of such payments shall in all instances either

  

 3 

 
(A) satisfy the conditions of an exception from Section 409A of the Code (e.g., the short-term deferrals exception described in Treasury Regulation Section 1.409A-1(b)(4)),
or (B) comply with Section 409A of the Code and provided, further, that in the absence of such terms regarding the timing of payments, such payments shall occur no later than the later of (1) the 15th day of the third month of the calendar year following the calendar
year in which the Participant’s right to payment ceased being subject to a substantial risk of forfeiture, and (2) the 15th day of the third month of the Company’s fiscal year following the Company’s fiscal year in which the
Participant’s right to payment ceased being subject to a substantial risk of forfeiture. 
 5.3. Maximum
Awards. No Participant shall receive a payment under the Plan with respect to any Performance Period having a value in excess of $3,000,000, which maximum amount shall be proportionately adjusted with respect to Performance Periods
that are less than or greater than one year in duration. 
 VI. General 
 6.1. Effective Date. The Plan shall be submitted to the stockholders of the Company for approval at the 2009
annual meeting of stockholders and, if approved by the affirmative vote of a majority of the shares of common stock present in person or represented by proxy at such meeting, shall become effective for Performance Periods beginning on and after
June 1, 2009. No Performance Period shall extend beyond May 31, 2014. In the event that the Plan is not approved by the stockholders of the Company, the Plan shall be null and void with respect to Participants who are “covered
employees” within the meaning of Section 162(m) of the Code. 
 6.2. Amendments and
Termination. The Board may amend the Plan as it shall deem advisable, subject to any requirement of stockholder approval required by applicable law, rule or regulation, including Section 162(m) of the Code. The Board may
terminate the Plan at any time. 
 6.3. Non-Transferability of Awards. No award under the Plan shall
be transferable other than by will, the laws of descent and distribution or pursuant to beneficiary designation procedures approved by the Company. Except to the extent permitted by the foregoing sentence, no award may be sold, transferred,
assigned, pledged, hypothecated, encumbered or otherwise disposed of (whether by operation of law or otherwise) or be subject to execution, attachment or similar process. Upon any attempt to sell, transfer, assign, pledge, hypothecate, encumber or
otherwise dispose of any such award, such award and all rights thereunder shall immediately become null and void. 
 6.4.
Tax Withholding. The Company shall have the right to require, prior to the payment of any amount pursuant to an award made hereunder, payment by the Participant of any Federal, state, local or other taxes which may be
required to be withheld or paid in connection with such award. 
 6.5. No Right of Participation or
Employment. No person shall have any right to participate in the Plan. Neither the Plan nor any award made hereunder shall confer upon any person any right to continued employment by the Company or any subsidiary or affiliate of the
Company or affect in any manner the right of the Company or any subsidiary or affiliate of the Company to terminate the employment of any person at any time without liability hereunder. 
 6.6. Designation of Beneficiary. If permitted by the Company, a Participant may file with the Committee a
written designation of one or more persons as such Participant’s beneficiary or beneficiaries (both primary and contingent) in the event of the Participant’s death. 
 Each beneficiary designation shall become effective only when filed in writing with the Committee during the Participant’s lifetime on
a form prescribed by the Committee. The spouse of a married Participant domiciled in a community property jurisdiction shall join in any designation of a beneficiary other than such spouse. The filing with the Committee of a new beneficiary
designation shall cancel all previously filed beneficiary designations. 
  

 4 

 If a Participant fails to designate a beneficiary, or if all designated beneficiaries of a
Participant predecease the Participant, then each outstanding award shall be payable to the Participant’s executor, administrator, legal representative or similar person. 
 6.7. Governing Law. The Plan and each award hereunder, and all determinations made and actions taken pursuant
thereto, to the extent not otherwise governed by the Code or the laws of the United States, shall be governed by the laws of the State of Delaware and construed in accordance therewith without giving effect to principles of conflicts of laws.

 6.8. Other Plans. Payments pursuant to the Plan shall not be treated as compensation for purposes
of any other compensation or benefit plan, program or arrangement of the Company or any of its subsidiaries, unless either (a) such other plan provides that compensation such as payments made pursuant to the Plan are to be considered as
compensation thereunder or (b) the Board or the Committee so determines in writing. Neither the adoption of the Plan nor the submission of the Plan to the Company’s stockholders for their approval shall be construed as limiting the power
of the Board or the Committee to adopt such other incentive arrangements as it may otherwise deem appropriate. 
 6.9.
Binding Effect. The Plan shall be binding upon the Company and its successors and assigns and the Participants and their beneficiaries, personal representatives and heirs. If the Company becomes a party to any merger,
consolidation or reorganization, then the Plan shall remain in full force and effect as an obligation of the Company or its successors in interest, unless the Plan is amended or terminated pursuant to Section 6.2. 
 6.10. Unfunded Arrangement. The Plan shall at all times be entirely unfunded and no provision shall at any time
be made with respect to segregating assets of the company for payment of any benefit hereunder. No Participant shall have any interest in any particular assets of the Company or any of its affiliates by reason of the right to receive a benefit under
the Plan and any such Participant shall have only the rights of an unsecured creditor of the Company with respect to any rights under the Plan. 
  

 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}]]